Roca Therapeutics

Uveal melanoma is a rare disease with a very poor prognosis. After treatment of the ocular tumor, 30% of patients develop neovascular glaucoma leading to enucleation (removal of the eye) and 30% of patients develop lethal metastatic uveal melanoma in just one year, due to lack of effective therapy. Roca Therapeutics' mission is to develop personalized treatments based on novel small molecules for metastatic uveal melanoma and associated ocular complications.